https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
0315). There were three adverse events not related to OFDI. OFDI achieved acceptable visualization of the vessel lumen without any adverse event related to it. After regulatory approval based on the present study, OFDI will be available as a new option of endovascular imaging for peripheral artery diseases in daily practiceTrial registration This study was registered in the Japanese Registry of Clinical Trials (jRCT 2052190025, https//jrct.niph.go.jp/latest-detail/jRCT2052190025 ). Treatment of anismus usually starts with bi
Like
Comment
Share
